Related Experiment Videos
Opiate antagonists in erectile dysfunction: a possible new treatment option? Results of a pilot study with naltrexone
H van Ahlen1, H J Piechota, H J Kias
1Department of Urology, University of Münster, Germany.
Abstract:
Opioids have an inhibitory effect on sexual functions in both animals and humans. Twenty patients with idiopathic, nonvascular, nonneurogenic erectile dysfunction were treated with the opiate receptor antagonist naltrexone in a randomized, placebo-controlled, double-blind study for 8 weeks. Libido and frequency of sexual intercourse were not significantly altered, but early-morning erections increased significantly under naltrexone therapy. This response was not related to levels of androgens or gonadotropins, neither was it dose dependent. There was no change in any of the measured parameters under placebo. Further clinical studies with the substance should be conducted to evaluate its possible role in the oral treatment of male impotence.
Insights
Opioid antagonists like naltrexone may improve male erectile function. This study found naltrexone significantly increased early-morning erections in men with impotence, suggesting a potential treatment.
Area of Science:
- Reproductive Endocrinology
- Neuropharmacology
- Urology
Background:
- Opioids are known to negatively impact sexual function in both humans and animals.
- Erectile dysfunction (ED) is a common condition affecting male sexual health.
Purpose of the Study:
- To investigate the efficacy of naltrexone, an opiate receptor antagonist, in treating idiopathic erectile dysfunction.
- To assess the effects of naltrexone on sexual function parameters in men with ED.
Main Methods:
- A randomized, placebo-controlled, double-blind study was conducted over 8 weeks.
- Twenty patients diagnosed with idiopathic, nonvascular, nonneurogenic erectile dysfunction participated.
- Naltrexone was administered to assess changes in libido, sexual intercourse frequency, and early-morning erections.
Main Results:
- Naltrexone therapy led to a significant increase in early-morning erections.
- Libido and the frequency of sexual intercourse did not show significant changes.
- The observed improvements were independent of androgen or gonadotropin levels and not dose-dependent.
Conclusions:
- Naltrexone shows potential as an oral treatment for male impotence, specifically improving nocturnal erections.
- Further clinical research is warranted to confirm its role in managing erectile dysfunction.
- The mechanism appears independent of hormonal regulation, suggesting a direct effect on opioid pathways influencing erectile function.